Company / Net Income
Inhibrx Biosciences, Inc. Net Income History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$140.1M
FY2025
5-year range
-$241.4M / -$140.1M
FY2023-FY2025
Trend
+42.0%
vs FY2024
Sector context
#125 of 216
Health Care
What the data says
At -$140M, Inhibrx Biosciences, Inc.'s net income ranks #125 of 216 in the Health Care sector. Improved from -$241M to -$140M over the past 2 years.
Based on SEC 10-K filings.
-$140M in FY2025.
Improved from -$241M to -$140M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#125 of 216 in Health CareTop 58% of 216This company -$140.1M Sector average $454.3M
▼
-130.8% below sector average
Key checks
Key Insights
- In FY2025, net income increased 42.0% year-over-year.
- Ranks #125 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$140.1M | +42.0% |
| FY2024 | -$241.4M | +0.0% |
| FY2023 | -$241.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026